Journal article
In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days.
Authors
Cervi A; Douketis J
Journal
Annals of Internal Medicine, Vol. 170, No. 12,
Publisher
American College of Physicians
Publication Date
June 2019
DOI
10.7326/acpj201906180-067
ISSN
1056-8751